{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:55:04Z","timestamp":1788188104104,"version":"build-2803163510"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ijcha.2024.101387","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:17:25Z","timestamp":1710980245000},"page":"101387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Inhibitory effect of rivaroxaban on protease-activated receptor-2 in circulating neutrophils among patients with atrial fibrillation"],"prefix":"10.1016","volume":"52","author":[{"given":"Makoto","family":"Nakano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-5236","authenticated-orcid":false,"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhi","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nochioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2024.101387_b0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvt343","article-title":"Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants","volume":"101","author":"Spronk","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcha.2024.101387_b0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1253\/circj.CJ-08-0817","article-title":"Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors","volume":"73","author":"Rashid","year":"2009","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcha.2024.101387_b0015","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/jnr.24013","article-title":"Reduction of intracerebral hemorrhage by rivaroxaban after tPA thrombolysis is associated with downregulation of PAR-1 and PAR-2","volume":"95","author":"Morihara","year":"2017","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ijcha.2024.101387_b0020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jjcc.2017.08.007","article-title":"Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation","volume":"71","author":"Kondo","year":"2018","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101387_b0025","doi-asserted-by":"crossref","first-page":"915","DOI":"10.5551\/jat.48405","article-title":"Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction","volume":"26","author":"Liu","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.ijcha.2024.101387_b0030","doi-asserted-by":"crossref","first-page":"e012195","DOI":"10.1161\/JAHA.119.012195","article-title":"Rivaroxaban, a direct factor Xa inhibitor, ameliorates hypertensive renal damage through inhibition of the inflammatory response mediated by protease-activated receptor pathway","volume":"8","author":"Ichikawa","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcha.2024.101387_b0035","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.freeradbiomed.2011.08.003","article-title":"Redox regulation of human protease-activated receptor-2 by activated factor X","volume":"51","author":"Jobi","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ijcha.2024.101387_b0040","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/jth.13595","article-title":"Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation","volume":"15","author":"Achilles","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcha.2024.101387_b0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcha.2024.101387_b0050","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2024.101387_b0055","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T07:33:00Z","timestamp":1720769580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906724000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":11,"alternative-id":["S2352906724000538"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101387","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory effect of rivaroxaban on protease-activated receptor-2 in circulating neutrophils among patients with atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101387"}}